BRPI0211844B8 - composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica - Google Patents
composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêuticaInfo
- Publication number
- BRPI0211844B8 BRPI0211844B8 BR0211844A BR0211844A BRPI0211844B8 BR PI0211844 B8 BRPI0211844 B8 BR PI0211844B8 BR 0211844 A BR0211844 A BR 0211844A BR 0211844 A BR0211844 A BR 0211844A BR PI0211844 B8 BRPI0211844 B8 BR PI0211844B8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- alkyl
- phenoxy
- pharmaceutically acceptable
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 3
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 239000011593 sulfur Chemical group 0.000 abstract 2
- 239000012190 activator Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/62—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
"composto e ativador de receptor delta ativado por proliferador de peroxissoma". um composto representado pela seguinte fórmula geral (i): (em que r^ 1^ representa fenila, etc, que pode ter substituintes selecionado dentre o grupo consistindo de alquila c~ 1-8~ alquila c~ 1-8~ tendo halogênio, halogênio, hidroxila, etc., r^ 2^ representa alquila c~ 1-8~, etc.; a representa oxigênio, enxofre, etc;, x representa cadeia alquileno c~ 1-8~, etc; y representa c(=o), ch=ch, etc.; r^ 3^, r^ 4^, e r^ 5^ cada representa hidrogênio, alquila c~ 1-8~, etc; b representa ch ou nitrogênio; z representa oxigênio ou enxofre; r^ 6^ e r^ 7^ representa, cada, hidrogênio, alquila c~ 1-8~, etc.; e r^ 8^ representa hidrogênio ou alquila c~ 1-8~, desde que pelo menos um dentre r^ 3^, r^ 4^ e r^ 5^ não é hidrogênio) ou um sal do composto; e um ativador de ppar-<sym> que contém o composto ou sal como o ingrediente ativo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001243734 | 2001-08-10 | ||
| PCT/JP2002/007897 WO2003016291A1 (en) | 2001-08-10 | 2002-08-02 | ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR δ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0211844A BR0211844A (pt) | 2004-08-31 |
| BRPI0211844B1 BRPI0211844B1 (pt) | 2019-08-27 |
| BRPI0211844B8 true BRPI0211844B8 (pt) | 2021-05-25 |
Family
ID=19073779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0211844A BRPI0211844B8 (pt) | 2001-08-10 | 2002-08-02 | composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7265137B2 (pt) |
| EP (1) | EP1424330B1 (pt) |
| JP (3) | JP4421895B2 (pt) |
| KR (1) | KR100901683B1 (pt) |
| CN (1) | CN1330641C (pt) |
| AT (1) | ATE526319T1 (pt) |
| AU (1) | AU2002323776B2 (pt) |
| BR (1) | BRPI0211844B8 (pt) |
| CA (1) | CA2457054C (pt) |
| CY (1) | CY1112130T1 (pt) |
| DK (1) | DK1424330T3 (pt) |
| ES (1) | ES2372813T3 (pt) |
| IL (2) | IL160304A0 (pt) |
| MX (1) | MXPA04001258A (pt) |
| PT (1) | PT1424330E (pt) |
| WO (1) | WO2003016291A1 (pt) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7105551B2 (en) * | 2000-12-20 | 2006-09-12 | Smithkline Beecham Corporation | Thiazole derivatives for treating PPAR related disorders |
| AU2002323776B2 (en) * | 2001-08-10 | 2008-07-31 | Nippon Chemiphar Co., Ltd. | Activator for peroxisome proliferator-responsive receptor Delta |
| JP4276074B2 (ja) * | 2001-10-12 | 2009-06-10 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
| WO2004093910A1 (ja) * | 2003-04-22 | 2004-11-04 | Astellas Pharma Inc. | ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤 |
| EP2100877B1 (en) | 2003-09-19 | 2012-01-25 | Janssen Pharmaceutica N.V. | 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| US20050203151A1 (en) * | 2003-12-19 | 2005-09-15 | Kalypsys, Inc. | Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions |
| US7554974B2 (en) * | 2004-03-09 | 2009-06-30 | Tekelec | Systems and methods of performing stateful signaling transactions in a distributed processing environment |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| JP2007536343A (ja) | 2004-05-05 | 2007-12-13 | ノボ ノルディスク アクティーゼルスカブ | Ｐｐａｒアゴニストとしてのフェノキシ酢酸誘導体 |
| EP1745014B1 (en) | 2004-05-05 | 2011-07-06 | High Point Pharmaceuticals, LLC | Novel compounds, their preparation and use |
| JPWO2006041197A1 (ja) * | 2004-10-14 | 2008-05-22 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤活性化受容体δの活性化剤 |
| JPWO2006090920A1 (ja) * | 2005-02-28 | 2008-07-24 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤活性化受容体δの活性化剤 |
| BRPI0610177A2 (pt) * | 2005-05-25 | 2016-11-29 | Nippon Chemiphar Co | composto ou um sal do mesmo, e, ativador para receptor ativado por proliferador de peroxissomo |
| US7943669B2 (en) | 2005-06-30 | 2011-05-17 | High Point Pharmaceuticals, Llc | Phenoxy acetic acids as PPAR delta activators |
| EP1940767A2 (en) * | 2005-09-07 | 2008-07-09 | Plexxikon, Inc. | Pparactive compounds |
| JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| WO2007039172A1 (en) * | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridyl-i, 2 , 4 -oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals |
| CA2624102A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| EA201101084A1 (ru) | 2005-12-22 | 2012-04-30 | ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Феноксиуксусные кислоты в качестве активаторов ppar дельта |
| US7649098B2 (en) * | 2006-02-24 | 2010-01-19 | Lexicon Pharmaceuticals, Inc. | Imidazole-based compounds, compositions comprising them and methods of their use |
| JP2009529512A (ja) | 2006-03-09 | 2009-08-20 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | 新規な化合物、それらの製造法、及び使用法 |
| AU2013202514B2 (en) * | 2006-04-18 | 2015-09-17 | Nippon Chemiphar Co., Ltd. | Activating agent for peroxisome proliferator activated receptor delta |
| ZA200809148B (en) * | 2006-04-18 | 2010-01-27 | Nippon Chemiphar Co | Activating agent for peroxisome proliferator activated receptor delta |
| UY30288A1 (es) | 2006-04-18 | 2007-08-31 | Janssen Pharmaceutica Nv | Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol |
| WO2007122970A1 (ja) * | 2006-04-20 | 2007-11-01 | Osaka University | 核内受容体に結合するリガンド |
| US8106070B2 (en) | 2006-10-20 | 2012-01-31 | Merck Sharp & Dohme Corp. | Substituted imidazoles as bombesin receptor subtype-3 modulators |
| RU2009118935A (ru) | 2006-10-20 | 2010-11-27 | Мерк энд Ко., Инк. (US) | Земещенные имидазолы в качестве модуляторов подтипа 3 бомбезиновых рецепторов |
| WO2008051405A1 (en) | 2006-10-20 | 2008-05-02 | Merck & Co., Inc. | Substituted imidazoles as bombesin receptor subtype-3 modulators |
| FR2910893A1 (fr) * | 2006-12-29 | 2008-07-04 | Genfit Sa | Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazolyl)-phenyl-propan-1-one substitues, preparations et utilisations. |
| RU2449789C2 (ru) * | 2007-05-21 | 2012-05-10 | Сэндзю Фармасьютикал Ко., Лтд. | Лекарственное средство, содержащее prarδ агонист |
| TW200920355A (en) * | 2007-09-06 | 2009-05-16 | Lexicon Pharmaceuticals Inc | Compositions and methods for treating immunological and inflammatory diseases and disorders |
| WO2009078981A2 (en) * | 2007-12-13 | 2009-06-25 | Sri International | Ppar-delta ligands and methods of their use |
| JP5474769B2 (ja) | 2008-04-15 | 2014-04-16 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤活性化受容体の活性化剤 |
| EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
| JP5357894B2 (ja) * | 2008-12-01 | 2013-12-04 | 田辺三菱製薬株式会社 | チアゾール環を含むカルボン酸誘導体およびその医薬用途 |
| JP2012116753A (ja) * | 2009-03-26 | 2012-06-21 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤活性化受容体の活性化剤 |
| CN102724978A (zh) * | 2009-08-14 | 2012-10-10 | 塞伦尼斯治疗公司 | 用于治疗或预防炎症或能量代谢/产生相关疾病的PPARδ配体的用途 |
| AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| MX348131B (es) | 2011-02-25 | 2017-05-26 | Merck Sharp & Dohme | Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos. |
| WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| ES2811087T3 (es) | 2013-09-09 | 2021-03-10 | Vtv Therapeutics Llc | Uso de agonistas de PPAR-delta para tratar la atrofia muscular |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| CN105237487B (zh) * | 2015-10-19 | 2017-10-10 | 安徽中医药大学 | 含川芎嗪基查尔酮芳氧烷酸类化合物、制备方法及其应用 |
| CN109562101A (zh) * | 2016-05-12 | 2019-04-02 | 日本化学药品株式会社 | 创伤治疗剂 |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| EP3558298B1 (en) | 2016-12-20 | 2026-03-11 | Merck Sharp & Dohme LLC | Antidiabetic spirochroman compounds |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| WO2022189856A1 (en) * | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089514A (en) | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
| GB9027023D0 (en) | 1990-12-12 | 1991-01-30 | Wellcome Found | Anti-atherosclerotic aryl compounds |
| HUT64023A (en) | 1991-03-22 | 1993-11-29 | Sandoz Ag | Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds |
| CA2090283A1 (en) | 1992-02-28 | 1993-08-29 | Nobuyuki Hamanaka | Phenoxyacetic acid derivatives |
| JP3722855B2 (ja) * | 1993-09-14 | 2005-11-30 | 武田薬品工業株式会社 | ２，４−オキサゾリジンジオン誘導体およびそれを含んでなる医薬 |
| GB9426448D0 (en) | 1994-12-30 | 1995-03-01 | Wellcome Found | Process |
| EP0751126A4 (en) | 1995-01-06 | 1998-05-13 | Toray Industries | BENZOCONDENSE HETEROCYCLIC DERIVATIVE AND ITS USE |
| CA2171702A1 (en) | 1995-03-14 | 1996-09-15 | Takashi Sohda | Benzofuran compounds and their use |
| WO1996035688A1 (en) | 1995-05-08 | 1996-11-14 | Nippon Chemiphar Co., Ltd. | 2,4-thiazolidinedione or oxazolidinedione derivatives and hypoglycemic agent |
| JP2000503984A (ja) | 1996-01-22 | 2000-04-04 | 藤沢薬品工業株式会社 | チアゾリルベンゾフラン誘導体およびその医薬組成物 |
| DE69723680T9 (de) | 1996-02-02 | 2004-11-04 | Merck & Co., Inc. | Antidiabetische mittel |
| US20020032330A1 (en) | 1996-12-24 | 2002-03-14 | Yutaka Nomura | Propionic acid derivatives |
| ES2320181T3 (es) * | 1997-07-24 | 2009-05-19 | Astellas Pharma Inc. | Composiciones farmaceuticas que tienen un efecto reductor del colesterol. |
| US6589969B1 (en) | 1998-10-16 | 2003-07-08 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| DK1206457T3 (da) * | 1999-08-27 | 2004-02-16 | Lilly Co Eli | Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER |
| TW200528436A (en) * | 1999-09-22 | 2005-09-01 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
| PE20011010A1 (es) * | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
| JP2001354671A (ja) | 2000-04-14 | 2001-12-25 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
| EP1310494B1 (en) | 2000-08-11 | 2012-01-25 | Nippon Chemiphar Co., Ltd. | PPAR (delta) ACTIVATORS |
| GB0031109D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| EP1371650A4 (en) * | 2001-03-23 | 2005-05-04 | Nippon Chemiphar Co | ACTIVATED RECEPTOR ACTIVATOR BY PEROXYSOME PROLIFIERS |
| GB0111523D0 (en) | 2001-05-11 | 2001-07-04 | Glaxo Group Ltd | Chemical compounds |
| AU2002323776B2 (en) * | 2001-08-10 | 2008-07-31 | Nippon Chemiphar Co., Ltd. | Activator for peroxisome proliferator-responsive receptor Delta |
-
2002
- 2002-08-02 AU AU2002323776A patent/AU2002323776B2/en not_active Expired
- 2002-08-02 DK DK02755779.2T patent/DK1424330T3/da active
- 2002-08-02 PT PT02755779T patent/PT1424330E/pt unknown
- 2002-08-02 IL IL16030402A patent/IL160304A0/xx unknown
- 2002-08-02 KR KR1020047002008A patent/KR100901683B1/ko not_active Expired - Fee Related
- 2002-08-02 CA CA2457054A patent/CA2457054C/en not_active Expired - Lifetime
- 2002-08-02 MX MXPA04001258A patent/MXPA04001258A/es active IP Right Grant
- 2002-08-02 AT AT02755779T patent/ATE526319T1/de active
- 2002-08-02 US US10/486,783 patent/US7265137B2/en not_active Expired - Lifetime
- 2002-08-02 ES ES02755779T patent/ES2372813T3/es not_active Expired - Lifetime
- 2002-08-02 BR BR0211844A patent/BRPI0211844B8/pt not_active IP Right Cessation
- 2002-08-02 EP EP02755779A patent/EP1424330B1/en not_active Expired - Lifetime
- 2002-08-02 WO PCT/JP2002/007897 patent/WO2003016291A1/ja not_active Ceased
- 2002-08-02 JP JP2003521216A patent/JP4421895B2/ja not_active Expired - Fee Related
- 2002-08-02 CN CNB028201892A patent/CN1330641C/zh not_active Expired - Lifetime
-
2004
- 2004-02-10 IL IL160304A patent/IL160304A/en unknown
-
2007
- 2007-07-31 US US11/888,493 patent/US7652045B2/en active Active
- 2007-07-31 US US11/888,492 patent/US7648999B2/en not_active Expired - Lifetime
-
2009
- 2009-02-16 JP JP2009032919A patent/JP2009102442A/ja active Pending
- 2009-09-03 JP JP2009203393A patent/JP5097180B2/ja not_active Expired - Fee Related
-
2011
- 2011-12-02 CY CY20111101199T patent/CY1112130T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7265137B2 (en) | 2007-09-04 |
| US20050054674A1 (en) | 2005-03-10 |
| BR0211844A (pt) | 2004-08-31 |
| ES2372813T3 (es) | 2012-01-26 |
| EP1424330A1 (en) | 2004-06-02 |
| CA2457054A1 (en) | 2003-02-27 |
| AU2002323776B2 (en) | 2008-07-31 |
| BRPI0211844B1 (pt) | 2019-08-27 |
| CN1568316A (zh) | 2005-01-19 |
| US7652045B2 (en) | 2010-01-26 |
| IL160304A0 (en) | 2004-07-25 |
| KR20040023741A (ko) | 2004-03-18 |
| JP2009280622A (ja) | 2009-12-03 |
| JP4421895B2 (ja) | 2010-02-24 |
| WO2003016291A1 (en) | 2003-02-27 |
| CA2457054C (en) | 2011-10-11 |
| EP1424330A4 (en) | 2004-10-27 |
| CN1330641C (zh) | 2007-08-08 |
| CY1112130T1 (el) | 2015-11-04 |
| IL160304A (en) | 2010-12-30 |
| EP1424330B1 (en) | 2011-09-28 |
| US20080009525A1 (en) | 2008-01-10 |
| DK1424330T3 (da) | 2012-01-16 |
| JP2009102442A (ja) | 2009-05-14 |
| KR100901683B1 (ko) | 2009-06-08 |
| US7648999B2 (en) | 2010-01-19 |
| ATE526319T1 (de) | 2011-10-15 |
| JP5097180B2 (ja) | 2012-12-12 |
| MXPA04001258A (es) | 2005-06-06 |
| PT1424330E (pt) | 2011-12-22 |
| JPWO2003016291A1 (ja) | 2004-12-02 |
| US20080009631A1 (en) | 2008-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1424330T3 (da) | Aktivator for peroxisom proliferator-responsiv receptor delta | |
| DE60232739D1 (de) | Aktivator des peroxisomproliferator-aktivierten rezeptors delta | |
| DE60315265D1 (de) | Stickstoffhaltige heterocyclische verbindung und arzneimittel davon | |
| NO306720B1 (no) | Sykliske ureaer og analoger som er anvendbare som retrovirale proteaseinhibitorer, farmasöytiske preparater omfattende disse og anvendelse av forbindelsene for fremstilling av farmasöytiske preparater | |
| PT976748E (pt) | Derivados de pirrolidina com actividade inibidora de fosfolipase a2 | |
| BRPI9908319B8 (pt) | composto amino cíclico, composição farmacêutica, medicamento contendo um composto amino cíclico ou um sal farmacologicamente aceitável do mesmo, e, uso de um composto amino cíclico ou um sal farmacologicamente aceitável do mesmo. | |
| AU5117890A (en) | Trifluromethylphenylazolylmethyloxiranes, the preparation thereof and the use thereof as crop protection agents | |
| ATE380172T1 (de) | Benzylaminanalogen | |
| ATE374750T1 (de) | Serotoninwiederaufnahme-inhibitoren | |
| DK0962457T3 (da) | Piperidoner som tachykininantagonister | |
| MX9206930A (es) | Nuevos compuestos | |
| BR0109573A (pt) | Composto ou uma pró-droga ou um sal farmacologicamente aceitável do mesmo, agente, composição farmacêutica, e, uso de um composto ou uma pró-droga ou um sal farmacologicamente aceitável do mesmo | |
| EA200200682A1 (ru) | Новые соединения n-бензилпиперазина, способ их получения и фармацевтические композиции, их содержащие | |
| ATE192141T1 (de) | Aromatische hydroxamsäure-verbindungen, ihre herstellung und verwendung | |
| EA200000116A1 (ru) | Противогрибковые соединения на основе 2,4,4-тризамещенных-1,3-диоксоланов | |
| DE60238847D1 (de) | Pyrimidinderivate enthaltendes medikament | |
| MY101628A (en) | Sulfonamide compounds and salts thereof, herbicidal compositions containing them, and process for producing them. | |
| EA200200462A1 (ru) | Производные 2-арилхинолина, их получение и терапевтическое применение | |
| NO20010244D0 (no) | Medikamenter inneholdende polyhydroksyalkylpyrazinderivater, deres fremstilling samt medikamenter inneholdende derivatene | |
| DK1098901T3 (da) | Nye 6-deoxyerythromycinderivater, fremgangsmåde til deres fremstilling samt deres anvendelse som lægemidler | |
| DE69407227D1 (de) | Die Verwendung von 2-Phenylmethylene-1-3'-(amino)-2-(hydroxy)-propoxy-imino-cyclohexane-Derivaten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/08/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/08/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 20A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2681 DE 24-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |